Investigation of the Molecular Signature of Senescence in Mesenchymal Stem Cells

Forough-Azam  Sayahpour; Marjan  Nejati; Mahya  Rouhollahi-Masoumi; Mohamadreza Baghaban  Eslaminejad; Sara  Taleahmad

doi:10.18502/ajmb.v18i2.21500

Forough-Azam Sayahpour Medical College of Wisconsin, Center of Cancer Discovery, Milwaukee, WI, USA
Marjan Nejati Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biolo-gy and Technology, ACECR, Tehran, Iran
Mahya Rouhollahi-Masoumi Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biolo-gy and Technology, ACECR, Tehran, Iran
Mohamadreza Baghaban Eslaminejad Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biolo-gy and Technology, ACECR, Tehran, Iran
Sara Taleahmad Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biolo-gy and Technology, ACECR, Tehran, Iran

DOI: https://doi.org/10.18502/ajmb.v18i2.21500

Keywords: Differentially expressed genes, Mesenchymal stem cells, Regenerative medicine, Senescence, Se-nescence-associated secretory phenotype

Abstract

Background: Mesenchymal Stem Cells (MSCs) play a pivotal role in regenerative medicine due to their multipotency and immunomodulatory properties. However, during in vitro expansion, MSCs undergo senescence, characterized by a decline in proliferation, impairment of differentiation potential, and altered secretory profiles, which limits their therapeutic efficacy. This study aimed to identify novel molecular regulators and network-level interactions underlying MSC senescence through microarray analysis of the GSE7888 dataset, comparing early and senescent MSCs.

Methods: A total of 4597 Differentially Expressed Genes (DEGs) were identified between early (passages 4-5) and senescent (passages 22-28) MSCs, with 2219 upregulated and 2379 downregulated. Key regulators such as CDKN1A (p21), CDK4, and CDK6 were implicated in cell cycle arrest and the progression of senescence. Pathway analysis highlighted the mTOR, FoxO, and p53 signaling pathways as key regulators of stress responses, metabolism, and aging. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis highlighted cellular processes, including protein transport and intracellular signaling, while protein-protein interaction networks identified high-connectivity nodes such as TP53, FOXO3, and MDM2. Senescent MSCs displayed phenotypic changes, including altered morphology and the emergence of the Senescence-Associated Secretory Phenotype (SASP), which impaired regenerative potential.

Results: The findings suggest that targeting the mTOR, FoxO, and p53 pathways could delay senescence and enhance MSC therapeutic potential. Interventions such as rapamycin and FoxO3 activators show promise in reversing senescence.

Conclusion: Future research should explore small molecules and gene-based therapies targeting senescence pathways to improve MSC-based regenerative strategies. These results provide a foundation for developing innovative approaches to optimize MSC applications in clinical therapies